Stem Cell Therapy in `Transition Period' Benefiting Devicemakers
Oct. 12, 2007 | Vol. 4 No. 201
Advanced therapies using cells are being commercialized rapidly and
are transitioning from development to implementation, a trend that
will work in favor of the medical device industry, Cytonome President
Lydia Villa-Komaroff said.
A number of trials have indicated cell therapy will be an effective
treatment, and one analyst has predicted the cell therapy market will
be worth $8.5 billion by 2016, Villa-Komaroff added, speaking at
AdvaMed 2007.
Cell therapy is in a transition period, shifting from development to
more practical issues of implementation, and medical devicemakers
have a critical role to play in this transition, she said.
The medical device industry touches every part of the process for
these therapies, from cell extraction to therapy evaluation, she
said, adding that the industry is uniquely qualified to lower the
risks and advance the practice of cellular medicine.
http://fdanews.
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:
Children's Neurobiological Solutions
http://www.CNSfoundation.org/
Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123
The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Change settings via the Web (Yahoo! ID required)
Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional
Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe
__,_._,___
